Abstract
purpose. Glaucoma is widely accepted as a neurodegenerative disease in which retinal ganglion cell (RGC) loss is initiated by a primary insult to the optic nerve head, caused, for example, by increased intraocular pressure (IOP). In some cases, the surviving RGCs, despite adequate IOP control, may continue to degenerate as a result of their heightened susceptibility to self-destructive processes evoked by the initial damage. In animal models of mechanical or biochemical injury to the optic nerve or retina, a T-cell–mediated immune response evoked by the insult helps to reduce this ongoing loss. The current study was conducted to find out whether the ability to resist the IOP-induced loss of RGCs in a rat model is affected by the immune system.
methods. The ocular veins and limbal plexus of rats of two strains differing in their resistance to experimental autoimmune encephalomyelitis (EAE) and in their ability to manifest a beneficial autoimmune response were laser irradiated twice to induce an increase in IOP. The pressure was measured weekly, and RGC losses were assessed 3 and 6 weeks after the first irradiation. To verify the existence of a relationship between the immune system and RGC survival, we assessed neuronal survival in Sprague-Dawley (SPD) rats devoid of mature T cells as well as after transferring splenocytes from Fisher rats, an EAE-resistant rat strain capable of manifesting T-cell–mediated neuroprotection, to rats of a major histocompatibility complex (MHC)–matched EAE-susceptible strain (Lewis), in which the ability to manifest such protective immunity is limited.
results. Both 3 and 6 weeks after the increase in IOP was initiated, the number of surviving RGCs in SPD rats, a strain in which a beneficial autoimmune response can be evoked spontaneously, was significantly higher than in Lewis rats. Moreover, in SPD rats that were thymectomized at birth, the number of surviving RGCs after an increase in IOP as adults was significantly diminished. Passive transfer of splenocytes from Fisher rats to Lewis rats significantly reduced the IOP-induced loss of RGCs in the latter.
conclusions. In rats of different strains, a similar increase in IOP results in differing amounts of RGC loss. This disparity was found to correlate with immune potency. These findings may explain why patients with glaucoma experience different degrees of visual loss after pressure reduction, even when the severity of the disease at the time of diagnosis is similar. The results have far-reaching prognostic and therapeutic implications.
Glaucoma is now recognized as belonging to a group of neurodegenerative diseases characterized by the slow, progressive degeneration of retinal ganglion cells (RGCs)
1 2 3 4 that causes a gradual loss of visual field and eventually leads to blindness. The primary cause of the disease is not yet known, and the factors contributing to its progression are not yet fully characterized. The current treatment of patients with glaucoma is limited to reduction of intraocular pressure (IOP), known to be one of the major risk factors for the disease.
5 It is clear, however, that the lowering of IOP, although significantly reducing the extent of neuronal loss, does not ensure cessation of the disease process, because the loss of RGCs may continue, even after the IOP has been reduced.
6 7 8 9 10 Recent studies of the association between IOP regulation and visual field loss after medical or surgical intervention showed that ongoing neuronal loss reflected in visual field tests can be diminished if the IOP is low (defined as below 14 mm Hg). Experience has shown, however, that neuronal loss may continue to occur after reduction of IOP to a level that, although above 14 mm Hg, is below the patient’s hypertensive level and even below the normal level.
11 Such IOPs may be difficult to reach, and therefore degeneration may continue.
It has been suggested by our group
4 that the ongoing loss of neurons in glaucoma may be explained, at least in part, by secondary factors resulting from the degeneration of neurons (RGCs and their fibers) that were involved in the primary insult caused, for example, by the increase in IOP. According to this view, although the primary insult does not directly affect all fibers and RGCs, it causes alterations in the neuronal environment (including changes in neurotransmitters, depletion of growth factors, influx of calcium into the cells, and formation of free radicals), which in turn increase the vulnerability of spared neurons. Such alterations (e.g., the abnormally high concentrations of glutamate and nitric oxide) have been demonstrated in patients with glaucoma,
12 13 as well as in monkeys with abnormally high IOP.
12 Similar changes have been observed in a rat model of partial optic nerve injury, often used for studies of secondary degeneration and neuroprotection.
14 15 Evidence of the presence of deleterious factors that may be associated with secondary degeneration of the optic nerve also was recently demonstrated in monkeys.
16 This view of the pathogenesis of glaucoma has prompted attempts to identify additional compounds that make the extracellular environment hostile to neurons and to find ways of inhibiting the activity of these compounds or circumventing their effects.
Using the simplified rat model of a single acute trauma to the optic nerve, our group discovered that mechanical (e.g., crush injury)
17 18 or biochemical (e.g., glutamate-induced) insults to the optic nerve or retina stimulate a physiological protective mechanism that is mediated by T cells.
17 18 19 20 It was postulated that this T-cell–mediated immune response is designed to help the body cope with the self-destructive processes induced by trauma,
20 21 22 23 and it was termed “protective autoimmunity.”
20 Rats or mice devoid of mature T cells showed a worse recovery from axonal injury or glutamate toxicity than matched control animals with normal immune systems.
17 18 24 Moreover, not all animals or strains are equally endowed with the ability to sustain an autoimmune response with beneficial outcome.
17 Animals that are inherently resistant (when challenged with myelin-associated antigens emulsified in adjuvant) to the development of a transient monophasic central nervous system (CNS) autoimmune disease, known as experimental autoimmune encephalomyelitis (EAE), recover better from optic nerve injury than EAE-susceptible animals.
17 Differences in recovery appear to be attributable to differences in the ability of a particular animal or strain to a manifest a spontaneously well-controlled autoimmune response with a beneficial outcome. In the present study, using a rat model, we showed that the ability to cope with a chronic condition of the visual system, such as increased IOP, is also immune dependent.
Examination of Immune System Involvement in IOP-Induced Neuronal Loss after Partial Crush Injury
To examine the role of the immune system in determining the extent of neuronal loss, we transferred splenocytes from Fisher rats, which are moderately resistant to EAE, to the EAE-susceptible Lewis rats. Splenocytes obtained from Fisher rats were injected intravenously into Lewis rats (3.5 × 108 per rat) immediately after the first laser session. Three weeks later, the retinas were retrogradely labeled with dextran tetramethylrhodamine and excised. As a control group, we used Lewis rats that underwent the same procedure but were injected intravenously either with PBS or with splenocytes derived from other Lewis rats.
Absence of T Cells in Resistant Strains Leads to a Larger Loss of RGCs after an Increase in IOP
This study shows that rats of two different strains, when subjected to an identical or near-identical insult induced by IOP, experienced RGC losses of different amounts. This difference was found to be linked to immune system activity.
High IOP is considered to be a major risk factor in glaucoma. However, in some patients with glaucoma the loss of RGCs continues despite therapeutic IOP reduction. There are at least three possible reasons for this: (1) insufficient IOP reduction
11 ; (2) emergence of additional risk factors during the course of the disease; and (3) increased susceptibility of the remaining neurons to the unfavorable conditions. The ongoing loss of RGCs in glaucoma may be partially attributable to a process of secondary degeneration occurring in an extracellular nerve environment made hostile to spared neurons as a consequence of the primary insult induced by IOP or other risk factors.
4 12 28 29 Research worldwide has been devoted to identifying the compounds and processes that may help explain why the damage continues to spread, even after normal pressure is restored.
13 16 30 31 The mechanisms of damage propagation seen in various acute and chronic degenerative conditions appear to have much in common. As an example, the ubiquitous neurotransmitter glutamate, a major mediator of chronic neurodegenerative disorders,
32 is a potential mediator of toxicity in animal models of acute optic nerve injury,
15 as well as in glaucoma.
13 Attempts have therefore been focused on ways to neutralize or diminish the toxicity of such mediators,
30 31 32 33 or at least to increase the ability of the neurons to resist the effects of the unfavorable environment.
Studies in our laboratory have demonstrated that the number of RGCs in rats or mice that survive a partial injury to the optic nerve or exposure to glutamate toxicity is a function of the availability of T-cell–mediated protective immunity; in the absence of mature T cells, more RGCs are lost.
17 19 22 Not all individuals or strains are equally capable of recruiting the protective aid of the immune system in response to optic nerve insults, and their ability to avoid the loss of RGCs after optic nerve insult correlates with their ability to resist the induction of EAE.
17 The T cells evidently exert their protective effect by assisting the microglia/macrophages to remove the sources of self-destruction (Butovsky et al., unpublished data, 2002, and Nevo et al., unpublished data, 2002).
In the present study a similar correlation was found between resistance to autoimmune disease and the ability to withstand an insult induced by an increase in IOP. The lower resistance to the IOP-induced RGC loss (seen in Lewis rats) was evidently attributable to immune system deficiency, as indicated by the beneficial effect in the Lewis rats replenished with splenocytes from Fisher rats, which are capable of manifesting protective T-cell–mediated immunity. Similar results were obtained in a rat model of optic nerve partial crush injury.
The difference in the RGC losses observed here between rats with a similar increase in IOP is in line with the general experience that the ability of individuals to tolerate increased pressure varies. It was not realized, until the present study, that the ability to tolerate pressure is related to immune system activity. This latter finding, however, is in line with the recent suggestion by our group that the immune system plays a pivotal role in protecting the organism, not only against invading pathogens, but also from potentially destructive self-components such as glutamate.
1 12 20 21 34 Thus, just as T-cell activity against foreign antigens confers protection from microbes, a T-cell response against self-antigens helps to protect against the threat of self-destruction. Rat strains may of course differ with respect to many other characteristics besides the ability to control the immune response. Nevertheless, the inherent relative advantage of SPD rats in resisting IOP was lost as a result of neonatal thymectomy, suggesting that—as in the case of optic nerve crush injury—strain-related differences are attributable, at least in part, to T cell function. In the present study we also showed that this suggestion is valid by demonstrating the similar effects of replenishment of susceptible rats with lymphocytes from resistant rats after insults induced by crush injury and by IOP. Additional factors that may contribute to IOP resistance cannot be ruled out.
The results of the present study thus suggest that the onset and prognosis of glaucoma may be decided by two sets of genetic factors: those that determine susceptibility to disease development and immune factors, which may determine progression. Thus, although the genes regulating the immune response are common to many neurodegenerative disorders,
35 36 37 predisposition to glaucoma is determined by those genes related to this disease.
35 36 37 If individuals with a predisposition to glaucoma also happen to have an immunologic background that confers resistance to CNS insults, the progression of visual field loss may be slow.
The finding that the body harnesses the immune system to help cope with an increase in IOP may seem to be in conflict with reported findings suggesting that immune-related factors have a negative effect on postinjury neuronal survival.
38 39 This apparent discrepancy can be resolved if we abandon the idea that immunity (or autoimmunity) is “good” or “bad,” and instead think in terms of (and seek to attain through therapy) well-regulated immune activity for CNS maintenance
20 21 23 which, in its onset, duration, specificity, and intensity,
40 is optimal. Seen in this context, our results argue in favor of immunomodulation as a therapy for glaucoma. Such an approach may be applicable, not only to glaucoma induced by high IOP, but also to normal-tension glaucoma.
Recent studies in our laboratory have shown that the RGC loss induced by high IOP, such as that induced by glutamate toxicity or acute crush injury, can be reduced by vaccination with the immunomodulatory drug Cop-1.
24 41 The results of morphologic analysis suggest that the immune system exerts its effect locally (i.e., within the eye). We suggest that the immune system, known to protect the body against harmful foreign antigens, is also the body’s own maintenance mechanism for protection against destructive self-compounds (such as glutamate). Such maintenance is mediated by a local innate response, which is regulated by an adaptive response in the form of specific T cells directed to self antigens.
By gaining a better understanding of the role of the immune system in glaucoma, and hence of individual differences in the immune response to the insult, we will improve our ability to design and develop treatments leading to better prevention of visual loss and disease progression.
Supported by Glaucoma Research Foundation, San Francisco, California; and Proneuron Biotechnologies, Ness-Ziona, Israel. MS holds the Maurice and Ilse Katz Professorial Chair in Neuroimmunology.
Submitted for publication August 17, 2001; revised March 6, 2002; accepted March 29, 2002.
Commercial relationships policy: C, P (MS); C (all others).
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Michal Schwartz, Department of Neurobiology, Weizmann Institute of Science, 76100 Rehovot, Israel;
michal.schwartz@weizmann.ac.il.
Strain | Normal | 1 Week | 2 Weeks | 3 Weeks | 6 Weeks |
Lewis (Right Eye) | 17.10 ± 1.20 | 28.32 ± 1.99 | 29.24 ± 2.58 | 28.42 ± 2.81 | 26 ± 2.72 |
| (n = 31) | (n = 24) | (n = 17) | (n = 21) | (n = 10) |
Lewis (Left Eye) | 16.49 ± 1.09 | 17.55 ± 2.01 | 17.22 ± 1.155 | 18.21 ± 1.26 | 20.23 ± 1.48 |
| (n = 31) | (n = 24) | (n = 17) | (n = 21) | (n = 10) |
SPD (Right Eye) | 17.37 ± 2.19 | 27.34 ± 3.79 | 27.32 ± 2.84 | 28.36 ± 3.01 | 24.10 ± 3.44 |
| (n = 23) | (n = 23) | (n = 13) | (n = 23) | (n = 13) |
SPD (Left Eye) | 19.41 ± 1.68 | 19.78 ± 1.82 | 19.28 ± 2.08 | 19.30 ± 2.18 | 19.83 ± 2.53 |
| (n = 23) | (n = 23) | (n = 13) | (n = 23) | (n = 13) |
Table 5. Loss of Neurons after Partial Crush Injury in Lewis Rats after Transfer of Splenocytes from Fisher Rats
Table 5. Loss of Neurons after Partial Crush Injury in Lewis Rats after Transfer of Splenocytes from Fisher Rats
Replenishment | Mean RGCs ± SD (per mm2) |
Fisher splenocyte | 828 ± 52 |
| (n = 5) |
Lewis splenocyte | 575 ± 54 |
| (n = 5) |
PBS injection | 664 ± 41 |
(n = 7) | |
Table 2. Number of Viable RGCs 3 and 6 Weeks after Induction of High IOP in Laser-Treated and Untreated Lewis and SPD Rats
Table 2. Number of Viable RGCs 3 and 6 Weeks after Induction of High IOP in Laser-Treated and Untreated Lewis and SPD Rats
Strain | Normal | 3 Weeks after Laser | | | 6 Weeks after Laser | | |
| Mean RGCs ± SD (per mm2) | Mean IOP ± SD (mm Hg) | Mean RGCs ± SD (per mm2) | Survival (%) | Mean IOP ± SD (mm Hg) | Mean RGCs ± SD (per mm2) | Survival (%) |
Lewis | 2525 ± 372 | 29.92 ± 2.38 | 1420 ± 272 | 53.9 | 25.62 ± 2.58 | 1267 ± 215 | 47.9 |
| (n = 5) | (n = 10) | | | (n = 7) | | |
SPD | 2664 ± 372 | 27.86 ± 2.91 | 1994 ± 161 | 74.2 | 24.8 ± 3.77 | 1838 ± 326 | 69.8 |
| (n = 6) | (n = 12) | | | (n = 21) | | |
Table 3. Lower RGC Survival after IOP Increase in SPD Rats Devoid of Mature T Cells
Table 3. Lower RGC Survival after IOP Increase in SPD Rats Devoid of Mature T Cells
Group | Mean RGCs ± SD (per mm2) |
Thymectomized SPD rats | 1256 ± 145 |
| (n = 6) |
Normal SPD rats | 1950 ± 148 |
| (n = 6) |
Table 4. IOP-Induced Loss of RGCs in Lewis Rats after Transfer of Splenocytes from Fisher Rats
Table 4. IOP-Induced Loss of RGCs in Lewis Rats after Transfer of Splenocytes from Fisher Rats
Group | Mean RGCs ± SD (per mm2) |
Lewis replenished with Fisher splenocytes | 1955 ± 176 |
| (n = 11) |
Lewis replenished with Lewis splenocytes | 1427 ± 177 |
| (n = 9) |
Lewis injected with PBS | 1418 ± 130 |
| (n = 5) |
Fisher injected with PBS | 1842 ± 72 |
| (n = 4) |
Schwartz M, Yoles E. Neuroprotection: a new treatment modality for glaucoma?. Curr Opin Ophthalmol
. 2000;11:107–111.
[CrossRef] [PubMed]Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. J Glaucoma
. 1998;7:165–169.
[PubMed]Quigley H A. Neuronal death in glaucoma. Prog Retinal Eye Res
. 1999;18:39–57.
[CrossRef] Schwartz M, Yoles E, Belkin M, Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J Glaucoma
. 1996;5:427–432.
[PubMed]Bonomi L, Marchini G, Marraffa M, Morbio R. The relationship between intraocular pressure and glaucoma in a defined population: data from the Egna-Neumarkt Glaucoma Study. Ophthalmologica
. 2001;215:34–38.
[CrossRef] [PubMed]Brubaker RF. Delayed functional loss in glaucoma: LII Edward Jackson Memorial Lecture. Am J Ophthalmol
. 1996;121:473–483.
[CrossRef] [PubMed]Cockburn DM, Bonomi L, Marchini G, Marraffa M, Morbio R. Does reduction of intraocular pressure (IOP) prevent visual field loss in glaucoma?. Am J Optom Physiol Opt
. 1983;60:705–711.
[CrossRef] [PubMed]AGIS Study Group. The Advanced Glaucoma Intervention Study (AGIS). 1: study design and methods and baseline characteristics of study patients. Control Clin Trials
. 1994;15:299–325.
[CrossRef] [PubMed]AGIS Study Group. The Advanced Glaucoma Intervention Study. 2: visual field test scoring and reliability. Ophthalmology
. 1994;101:1445–1455.
[CrossRef] [PubMed]AGIS Study Group. The Advanced Glaucoma Intervention Study (AGIS). 3: baseline characteristics of black and white patients. Ophthalmology
. 1998;105:1137–1145.
[CrossRef] [PubMed]AGIS Study Group. The Advanced Glaucoma Intervention Study (AGIS). 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol
. 2000;130:429–440.
[CrossRef] [PubMed]Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol
. 1996;114:299–305.
[CrossRef] [PubMed]Liu B, Neufeld AH. Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch Ophthalmol
. 2001;119:240–245.
[PubMed]Yoles E, Schwartz M. Evidence for secondary degeneration of spared neurons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol
. 1998;153:1–7.
[CrossRef] [PubMed]Yoles E, Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol
. 1998;116:906–910.
[CrossRef] [PubMed]Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA, D’Anna SA, Kerrigan D, Pease ME. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci
. 2001;42:975–982.
[PubMed]Kipnis J, Yoles E, Schori H, Hauben E, Shaked I, Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci
. 2001;21:4564–4571.
[PubMed]Yoles E, Hauben E, Palgi O, et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci
. 2001;21:3740–3748.
[PubMed]Schori H, Yoles E, Kipnis J, Schwartz M. Glutamate toxicity in the central nervous system is balanced by a beneficial T-cell-dependent autoimmune activity. J Neuroimmunol
. 2001;119:199–204.
[CrossRef] [PubMed]Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med
. 1999;5:49–55.
[CrossRef] [PubMed]Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci
. 1999;22:295–299.
[CrossRef] [PubMed]Schwartz M, Kipnis J. Genetic control of immune response to trauma: vaccination for acute and chronic CNS degenerative disorders. Trends Mol Med
. 2001;7:252–258.
[CrossRef] [PubMed]Schwartz M, Cohen IR. Autoimmunity can benefit self-maintenance. Immunol Today
. 2000;21:265–268.
[CrossRef] [PubMed]Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA
. 2001;98:3398–3403.
[CrossRef] [PubMed]Jia L, Cepurna WO, Johnson EC, Morrison JC. Effect of general anesthetics on IOP in rats with experimental aqueous outflow obstruction. Invest Ophthalmol Vis Sci
. 2000;41:3415–3419.
[PubMed]Sawada A, Neufeld AH. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp Eye Res
. 1999;69:525–531.
[CrossRef] [PubMed]Kunz HW, Cortese Hassett AL, Inomata T, Misra DN, Gill TJ, III. The RT1.G locus in the rat encodes a Qa/TL-like antigen. Immunogenetics
. 1989;30:181–187.
[CrossRef] [PubMed]Kawai SI, Vora S, Das S, Gachie E, Becker B, Neufeld AH. Modeling of risk factors for the degeneration of retinal ganglion cells after ischemia/reperfusion in rats: effects of age, caloric restriction, diabetes, pigmentation, and glaucoma. FASEB J
. 2001;15:1285–1287.
[PubMed]Shareef S, Sawada A, Neufeld AH. Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure. Invest Ophthalmol Vis Sci
. 1999;40:2884–2891.
[PubMed]Hare W, WoldeMussie E, Lai R, et al. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol
. 2001;45(suppl 3)S284–S289.discussion S295–S296
[CrossRef] [PubMed]Hof PR, Lee PY, Yeung G, Wang RF, Podos SM, Morrison JH. Glutamate receptor subunit GluR2 and NMDAR1 immunoreactivity in the retina of macaque monkeys with experimental glaucoma does not identify vulnerable neurons. Exp Neurol
. 1998;153:234–241.
[CrossRef] [PubMed]Faden AI. Experimental neurobiology of central nervous system trauma. Crit Rev Neurobiol
. 1993;7:175–186.
[PubMed]Melena J, Osborne NN. Voltage-dependent calcium channels in the rat retina: involvement in NMDA-stimulated influx of calcium. Exp Eye Res
. 2001;72:393–401.
[CrossRef] [PubMed]Schwartz M. Beneficial autoimmune T cells and posttraumatic neuroprotection. Ann NY Acad Sci
. 2000;917:341–347.
[PubMed]Colomb E, Nguyen T, Bechetoille A, et al. Association of a single nucleotide polymorphism in the TIGR/MYOCILIN gene promoter with the severity of primary open-angle glaucoma. Clin Genet
. 2001;60:220–225.
[PubMed]Tamm ER, Russell P. The role of myocilin/TIGR in glaucoma: results of the Glaucoma Research Foundation catalyst meeting in Berkeley, California, March 2000. J Glaucoma
. 2001;10:329–339.
[CrossRef] [PubMed]Lindsey JD, Gaton DD, Sagara T, Polansky JR, Kaufman PL, Weinreb RN. Reduced TIGR/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment. Invest Ophthalmol Vis Sci
. 2001;42:1781–1786.
[PubMed]Yang J, Patil RV, Yu H, Gordon M, Wax MB. T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. Am J Ophthalmol
. 2001;131:421–426.
[CrossRef] [PubMed]Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia
. 2000;32:42–50.
[CrossRef] [PubMed]Schwartz M, Kipnis J. Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift. Neuroscientist. .In press
Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA
. 2000;97:7446–7451.
[CrossRef] [PubMed]